GB2113545A - Treatment of migraine - Google Patents

Treatment of migraine Download PDF

Info

Publication number
GB2113545A
GB2113545A GB08201910A GB8201910A GB2113545A GB 2113545 A GB2113545 A GB 2113545A GB 08201910 A GB08201910 A GB 08201910A GB 8201910 A GB8201910 A GB 8201910A GB 2113545 A GB2113545 A GB 2113545A
Authority
GB
United Kingdom
Prior art keywords
migraine
tryptophan
codeine
mgs
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB08201910A
Inventor
Selwyn Leon Dexter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAYRON INTERNATIONAL Inc
Original Assignee
MAYRON INTERNATIONAL Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAYRON INTERNATIONAL Inc filed Critical MAYRON INTERNATIONAL Inc
Priority to GB08201910A priority Critical patent/GB2113545A/en
Publication of GB2113545A publication Critical patent/GB2113545A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions for treating migraine comprise a mixture of 1-tryptophan or 5-hydroxytryptophan and a centrally acting analgesic e.g. codeine. A peripherally acting analgesic can also be present.

Description

SPECIFiCATION PharmEne; tical composition This invention relates to pharmaceutical compositions for the treatment of migraine.
Migraine, in both its common and classical forms, and its associated disorders, is estimated to affect from 8-12% of the population. Numerous compounds have been proposed for the treatment of migraine both on a preventative basis and on an acute basis, but the need still exists for an effective anti-migraine treatment.
In the treatment of acute migraine, it is known that centrally acting analgesics such as codeine, morphine, pethidine are often ineffective in alleviating the headaches associated with common and classical migraines.
In accordance with the present invention, it has been found that 1 - tryptophan, or 5 - hydroxytryptophan, which is a known metabolite of 1 tryptophan, is a useful adjunct to centrally acting analgesics in the alleviation of the acute symptoms of migraine. The use of 1 - tryptophan in migraine treatment has been discussed in some detail in 'Headache', Volume 18, No.3, (July1978) pace 161, but combination thereby in conjunclion with centrally acting anagesics is not discussed.
In one aspect, the present invention provides a pharmaceutical composition for the treatment of migraine comprising in admixture 1 -tryptophan, or 5 - hydroxytryptophan, and a centrally acting analgesic, preferably codeine.
in another aspect, the present invention provides a method of alleviating the acute symptoms of migraine which comprises administering both 1 - tryptophan, of 5 - hydrnxytryptophan, and a centrally acting analgesic, preferably codeine.
The phatmaceutical compositions of the present invention are preferably in tablet form for oral administration comprising 1 - tryptophan, or 5 hydrnxytryptophan, and the centrally acting analgesic, e.g. codeine, in admixture in a tabletting carrier.
If desired the composition may also include a peripherally acting analgesic, e.g. asprin, phenacetin or paracetamol, to provide quicker relief of acute symptoms.
In place of codeine, other centrally acting analgesics may be used including morphine, papaverine, noscapine, narceine, dihydrocodeine, dihydromorphinone, oxymorphone, methyldihydromorphineone, heroin, pathidine, alphaprodine, anileridine, ethoheptazine methadone, dipapanone, de xtrapropoxyphene, phenazocine, pentazocine, fen- tanyl and tilidine. Codeine is, however, preferred.
In the combination therapy of the present invention the effective dose range of 1 -tryptophan, or 5 hydroxytryptophan is from 5-3000 mgs, four to six hourly, preferably 500-1500 mgs, and from 5-100 mgs, codeine preferably 10-30 mgs. Tablets for oral adminstration will be formulated accordingly, conveniently each as a single dosage unit containing from 5-3000 mgs, preferably 5-1500 mgs, 1 - tryptophan, or 5-hydroxytryptophan, and from 5-100 mgs. codeine, preferably 10-30 mgs.
Other formulations, e.g. liquid suspensions, for oral or for rectal administration will be obvious to those slvilied in the art.
1. A pharmaceutical compositionforthetreat- ment of migraine comprising in admixture 1 tryptophan, or 5 - hydroxytryptophan, and a centrally acting analgesic.
2. A pharmaceutical composition according to claim 1, wherein said analgesic is codeine.
3. A composition according to claim 1 or 2 additionally containing a peripherally acting analgesic.
4. A composition according to claim 3, wherein the peripherally acting analgesic is aspirin, phenacetin or paracetamol.
5. A composition according to any one of the preceding claims in tablet form.
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (5)

**WARNING** start of CLMS field may overlap end of DESC **. SPECIFiCATION PharmEne; tical composition This invention relates to pharmaceutical compositions for the treatment of migraine. Migraine, in both its common and classical forms, and its associated disorders, is estimated to affect from 8-12% of the population. Numerous compounds have been proposed for the treatment of migraine both on a preventative basis and on an acute basis, but the need still exists for an effective anti-migraine treatment. In the treatment of acute migraine, it is known that centrally acting analgesics such as codeine, morphine, pethidine are often ineffective in alleviating the headaches associated with common and classical migraines. In accordance with the present invention, it has been found that 1 - tryptophan, or 5 - hydroxytryptophan, which is a known metabolite of 1 tryptophan, is a useful adjunct to centrally acting analgesics in the alleviation of the acute symptoms of migraine. The use of 1 - tryptophan in migraine treatment has been discussed in some detail in 'Headache', Volume 18, No.3, (July1978) pace 161, but combination thereby in conjunclion with centrally acting anagesics is not discussed. In one aspect, the present invention provides a pharmaceutical composition for the treatment of migraine comprising in admixture 1 -tryptophan, or 5 - hydroxytryptophan, and a centrally acting analgesic, preferably codeine. in another aspect, the present invention provides a method of alleviating the acute symptoms of migraine which comprises administering both 1 - tryptophan, of 5 - hydrnxytryptophan, and a centrally acting analgesic, preferably codeine. The phatmaceutical compositions of the present invention are preferably in tablet form for oral administration comprising 1 - tryptophan, or 5 hydrnxytryptophan, and the centrally acting analgesic, e.g. codeine, in admixture in a tabletting carrier. If desired the composition may also include a peripherally acting analgesic, e.g. asprin, phenacetin or paracetamol, to provide quicker relief of acute symptoms. In place of codeine, other centrally acting analgesics may be used including morphine, papaverine, noscapine, narceine, dihydrocodeine, dihydromorphinone, oxymorphone, methyldihydromorphineone, heroin, pathidine, alphaprodine, anileridine, ethoheptazine methadone, dipapanone, de xtrapropoxyphene, phenazocine, pentazocine, fen- tanyl and tilidine. Codeine is, however, preferred. In the combination therapy of the present invention the effective dose range of 1 -tryptophan, or 5 hydroxytryptophan is from 5-3000 mgs, four to six hourly, preferably 500-1500 mgs, and from 5-100 mgs, codeine preferably 10-30 mgs. Tablets for oral adminstration will be formulated accordingly, conveniently each as a single dosage unit containing from 5-3000 mgs, preferably 5-1500 mgs, 1 - tryptophan, or 5-hydroxytryptophan, and from 5-100 mgs. codeine, preferably 10-30 mgs. Other formulations, e.g. liquid suspensions, for oral or for rectal administration will be obvious to those slvilied in the art. CLAIMS
1. A pharmaceutical compositionforthetreat- ment of migraine comprising in admixture 1 tryptophan, or 5 - hydroxytryptophan, and a centrally acting analgesic.
2. A pharmaceutical composition according to claim 1, wherein said analgesic is codeine.
3. A composition according to claim 1 or 2 additionally containing a peripherally acting analgesic.
4. A composition according to claim 3, wherein the peripherally acting analgesic is aspirin, phenacetin or paracetamol.
5. A composition according to any one of the preceding claims in tablet form.
GB08201910A 1982-01-22 1982-01-22 Treatment of migraine Withdrawn GB2113545A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08201910A GB2113545A (en) 1982-01-22 1982-01-22 Treatment of migraine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08201910A GB2113545A (en) 1982-01-22 1982-01-22 Treatment of migraine

Publications (1)

Publication Number Publication Date
GB2113545A true GB2113545A (en) 1983-08-10

Family

ID=10527832

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08201910A Withdrawn GB2113545A (en) 1982-01-22 1982-01-22 Treatment of migraine

Country Status (1)

Country Link
GB (1) GB2113545A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004170A1 (en) * 1986-12-13 1988-06-16 Joachim Kamprad Pain-killer
EP0478778A1 (en) * 1989-06-15 1992-04-08 Taisho Pharmaceutical Co. Ltd Antitussive

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004170A1 (en) * 1986-12-13 1988-06-16 Joachim Kamprad Pain-killer
US5216019A (en) * 1986-12-13 1993-06-01 Joachim Kamprad Pain killer
EP0478778A1 (en) * 1989-06-15 1992-04-08 Taisho Pharmaceutical Co. Ltd Antitussive
EP0478778A4 (en) * 1989-06-15 1992-10-07 Taisho Pharmaceutical Co. Ltd Antitussive

Similar Documents

Publication Publication Date Title
CA2296336A1 (en) Analgesic compositions comprising anti-epileptic compounds and methods of using same
ES8505519A1 (en) Analgesic, antagonist, and/or anorectic 14-fluoromorphinans.
AU584234B2 (en) A pharmaceutical composition for the relief of mild to severe pains and for the treatment of inflammation in muscle-skeletal disorders
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
NZ508526A (en) Opioid formulations for treating pain
CA1135189A (en) Analgesic tablet
CA2163197A1 (en) Tri(platinum) complexes
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
US3008874A (en) Pharmaceutical compositions
RU94045866A (en) Use of bis-phenylalkylpiperazines for treatment of disorders caused by substance abuse, method of treatment
GB2113545A (en) Treatment of migraine
MD1521F2 (en) Methods of thrombus forming inhibition, methods of treatment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states
GB2113544A (en) Treatment of migraine
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
GB2113546A (en) Treatment of migraine
EP0099186B1 (en) Pharmaceutical compositions
US4730007A (en) Novel analgesic compositions
CA2208111C (en) Method of enhancing cognition
HU193845B (en) Process for preparing synergic pharmaceutical preparations comprising flupyrthine and 4-acetamido-phenol
AU605538B2 (en) Pharmaceutical unit
EP0901376A1 (en) Malatonin in combination with analgesics
ES8505365A1 (en) Process for preparing base salts of piroxicam deposited on a pharmaceutically-acceptable carrier.
IL70407A (en) Synergistic analgesic pharmaceutical compositions in unit dosage form,comprising an analgesic agent and hydroxyzine
KR920017653A (en) Antitumor Compositions Containing Flunarizine
US4380540A (en) Tablets

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)